Prediction of pregnancy complications based on cardiovascular miRNA expression profiles

By measuring specific miRNA levels in peripheral venous whole blood during the first trimester, the method effectively predicts pregnancy complications like PE, FGR, GH, SGA, and PTB with high sensitivity and reduced false positives, addressing the limitations of current clinical methods.

JP2024543591APending Publication Date: 2024-11-21GENESPECTOR INNOVATIONS SRO
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024532948
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-13
Filing Date
2022-12-13
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current clinical methods for predicting pregnancy complications such as preeclampsia (PE), fetal growth restriction (FGR), gestational hypertension (GH), gestational excess (SGA), preterm birth (PTB), and chronic hypertension (CHH) are limited in their predictive capability, particularly during the first trimester, and often fail to detect these conditions early enough for effective intervention.

Method used

Measurement of specific miRNA levels in peripheral venous whole blood during the first trimester using RT-qPCR, identifying a subset of 25 miRNAs that can predict these complications with high sensitivity and reliability, including miR-146a-5p, miR-181a-5p, miR-155-5p, and others, allowing for early detection of PE, FGR, GH, SGA, and PTB.

Benefits of technology

The method achieves early and accurate prediction of pregnancy complications with improved sensitivity and reduced false positives, outperforming existing algorithms by identifying conditions like PE in 53.0% of cases, FGR in 40.2%, PTB in 52.8%, and SGA in 83.8%, with CHH detection at 79.3%, all with a false positive rate of 10%.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543591000049
    Figure 2024543591000049
  • Figure 2024543591000050
    Figure 2024543591000050
  • Figure 2024543591000051
    Figure 2024543591000051
Patent Text Reader

Abstract

A method for predicting pregnancy complications such as preeclampsia, fetal growth restriction, pregnancy-induced hypertension, small for gestational age, and premature birth, and a method for detecting chronic hypertension. Pregnant women are screened to measure the expression profile of one or more miRNAs in peripheral venous whole blood collected during the period from 10 to 13 weeks of pregnancy, while the one or more miRNAs are miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-1 00-5p, miR-103a-3p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p and miR-574-3p.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of molecular biology methods, mainly the analysis of non-coding nucleic acids and expression markers, in particular microRNAs (miRNAs), using quantitative reverse transcription polymerase chain reaction (RT-qPCR), and their use in screening for predicting the occurrence of adverse conditions in pregnancy. [Background technology]

[0002] During pregnancy, the mother or fetus may experience several complications that contribute significantly to maternal and perinatal morbidity and mortality. These are mainly preeclampsia (PE), fetal growth restriction (FGR), gestational hypertension (GH), small for gestational age (SGA), and preterm birth (PTB) in the form of spontaneous preterm birth (SPTB) or premature rupture of membranes (PPROM). Furthermore, chronic hypertension (CHH) is considered a risk factor for the development of PE. In addition to serious threats to the health or life of the mother and fetus, these complications cause irreversible changes in the metabolism or cardiovascular and cerebrovascular systems of the mother and her child, which may remain undetected and whose symptoms may manifest themselves over several years, as is known from the scientific literature, for example from the literature Hromadnikova et al., Int. J. Mol. Sci. 2020, 21 (21), p 8413 (Non-Patent Document 1) or Hromadnikova et al., J. Pers. Med. 2021, 11, p 39 (Non-Patent Document 2). The aim of modern medicine is therefore to predict these complications in due course and, ideally, to prevent their occurrence or at least mitigate their course and consequences.

[0003] The current standard in clinical practice is a prediction model based on algorithm-processed data such as maternal demographic data, personal and obstetric history, clinical characteristics (body mass index, mean arterial pressure), results of ultrasound examination of the uterine arteries, and measurements of serum analytes such as beta-hCG (free beta subunit of human chorionic gonadotropin), PAPP-A (pregnancy-associated plasma protein A) and PIGF (placental growth factor). Tests are performed during the first trimester and the results are presented as the probability of developing pregnancy complications in the form of trisomy 21, trisomy 18, trisomy 13, as well as PE and FGR. In cases where the probability of developing PE increases, the use of low-dose acetylsalicylic acid is then indicated. However, the drawback of this prediction model is its inability to predict GH, another of the complications mentioned above, and furthermore clinical data shows that this model does not predict PE, FGR, SGA and PTB well. Clinical data show that this algorithm predicts PE well in only one third of women who develop this complication during pregnancy, and FGR in only about one quarter of women, so the aim is also to find a reliable method that can predict other pregnancy complications.

[0004] Methods for linking the above-mentioned pregnancy complications with changes in the epigenetic profile of cardiovascular microRNAs (miRNAs) in mothers and children are known from Czech patents 308102 and 308178. miRNAs are small non-coding RNA molecules of 18-25 nucleotides in length that affect and regulate gene expression at the post-transcriptional level. Several tissues have characteristic miRNA expression profiles. During pathological processes, this expression profile can be altered long-term or irreversibly and can be used for diagnosis. The above documents describe postpartum and postnatal changes in the expression profile of 29 miRNAs that act on metabolic functions and the cardiovascular system and are induced by pregnancy complications (GH, PE, FGR). By measuring the levels of miRNA biomarkers in peripheral venous whole blood, it was possible to predict the susceptibility to cardiovascular diseases in mothers who developed pregnancy complications, as well as in their children. However, the knowledge available from these cited documents cannot be used to develop methods to predict complications during the first trimester, i.e., between 10 and 13 weeks of pregnancy, since the observed changes in miRNA expression profiles result from previous pregnancy complications that usually only appear in the third trimester, i.e., after 20 weeks of pregnancy. In other words, the increase or decrease in a given miRNA level after experiencing a pregnancy complication does not correspond to these values ​​before the onset of the complication in any way, but is completely independent. Since the techniques described in the cited patent documents are based on the changes caused by the onset and progression of a given pregnancy complication, these changes cannot be used to predict these complications before their onset.

[0005] The presence of altered miRNA expression profiles in placental tissues of patients who experienced PE, FGR or GH during pregnancy is known from scientific literature, for example from the references Hromadnikova et al., PLoS ONE 2015, 10(9) (Non-Patent Document 3), Zhang et al., Am. J. Obstet. Gynecol. 2010, 202, p466 (Non-Patent Document 4), Lykoudi et al., Placenta 2018, 61, p24 (Non-Patent Document 5), or Choi et al., Placenta 2013, 34, p799 (Non-Patent Document 6). These findings were obtained retrospectively by analyzing collected placental tissues. Literature Han et al., Bratisl. Med. J. 2017, 118(9), p523 (Non-Patent Document 7) suggests the possible use of miR-145 as a marker to predict the onset of PE, but only tested miR-145 expression in placental tissue after birth. Licini et al., Trans-LRes. 2021, 228, p13 (Non-Patent Document 8) suggests the possible use of miR-125b as a plasma marker to predict the onset of PE at 12 weeks of pregnancy, but this PE prediction model is based on a combination of miR-125b, pre-pregnancy BMI and gestational age at delivery, and gestational age cannot be applied in principle to a given PE prediction.

[0006] Furthermore, examples of changes in selected circulating miRNA levels during suspected PE symptoms were described in the period from 24 to 36 weeks of gestation (Munaut et al., Biomed. Rep. 2016, 5, p686 (Non-Patent Document 9)). Several circulating miRNAs have been proposed for use as markers predicting PE, but only severe variants thereof (Ura et al., Taiwan. J. Obstet. Gynecol. 2014, 53, p232 (Non-Patent Document 10)). Placenta-specific circulating miRNAs, i.e. miRNAs that are exclusively expressed in placental tissue, have been proposed for use to predict PE (Hromadnikova et al., PLoS ONE 2017, 12(2) (Non-Patent Document 11)) or PE, FGR and GH (Hromadnikova et al., Int. J. Mol. Sci. 2019, 20, p2972 (Non-Patent Document 12)). The cited literature describes markers that circulate freely in serum or plasma or as part of plasma exosomes. Processing of plasma exosomes is a difficult and laborious process, which is not suitable for widespread use in clinical practice. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Czech Patent Invention No. 308102 [Patent Document 2] Czech Patent Invention No. 308178 [Non-patent literature]

[0008] [Non-Patent Document 1] Hromadnikova et al.,Int.J.Mol.Sci.2020,21(21),p8413 [Non-Patent Document 2] Hromadnikova et al.,J.Pers.Med.2021,11,p39 [Non-Patent Document 3] Hromadnikova et al., PLoS ONE 2015, 10(9) [Non-Patent Document 4] Zhang et al., Am. J. Obstet. Gynecol. 2010, 202, p466 [Non-Patent Document 5] Lykoudi et al., Placenta 2018, 61, p24 [Non-Patent Document 6] Choi et al., Placenta 2013, 34 p799 [Non-Patent Document 7] Han et al., Bratisl. Med. J. 2017, 118(9), p523 [Non-Patent Document 8] Licini et al., Trans-LRes. 2021, 228, p13 [Non-Patent Document 9] Munaut et al., Biomed. Rep. 2016, 5, p686 [Non-Patent Document 10] Ura et al., Taiwan. J. Obstet. Gynecol. 2014, 53, p232 [Non-Patent Document 11] Hromadnikova et al., PLoS ONE 2017, 12(2) [Non-Patent Document 12] Hromadnikova et al., Int. J. Mol. Sci. 2019, 20, p2972 [Summary of the Invention] [Problems to be Solved by the Invention]

[0009] The object of the present invention is to eliminate the shortcomings of the prior art by developing a method that can be easily used on a large scale even in molecular genetic laboratories with general facilities, and that can correctly and reliably predict not only the frequently discussed PE and FGR, but also GH, SGA and PTB, which have only a small possibility of prediction in current clinical practice, and further detect CHH as a risk factor that may potentially go undetected in many women. [Means for solving the problem]

[0010] The present invention reports the expression of 25 specific miRNAs (miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-100-5p, miR-103-5p, miR-104-5p, miR-105-5p, miR-106-5p, miR-107-5p, miR-108-5p, miR-109-5p, miR-210-5p, miR-211-5p, miR-212-5p, miR-213-5p, miR-214-5p, miR-215-5p, miR-216-5p, miR-217-5p, miR-218-5p, miR-219-5p, miR-220-5p, miR-225-5p, miR-226-5p, miR-227-5p, miR-228-5p, miR-229-5p, miR-229-5p, miR-228-5p, miR-229-5p, miR-229-5p, miR-230-5p, miR-231-5p, miR-232-5p, miR-233-5p, miR-234-5p, miR-235-5p, miR-236-5p, miR-237-5p, miR-238-5p, miR-239-5p, miR-239-5p, miR-239-5p, miR-239-5p, miR The miRNAs are based on measuring the levels of miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p) by RT-qPCR. By selecting a suitable subset from this miRNA group, it is possible to predict the onset of PE, FGR, GH, SGA, and PTB and detect CHH with high probability and reliability.

[0011] Although the association of changes in the levels of the above miRNAs with current or past pregnancy complications in the form of PE or FGR has already been presented in the scientific literature and is therefore known from the prior art, its predictive use is not obvious or easily inferred from these documents, due to the large number of miRNAs described, the high variability of possible changes in expression levels, and the need to select an unknown subset of markers to predict individual pregnancy complications.

[0012] The method was developed based on the analysis of selected samples from 12,000 women in the first trimester of pregnancy, statistical processing of the results of these analyses, and comparison with the subsequent course of pregnancies of the monitored women.

[0013] First, the collected blood was processed into a leukocyte lysate. The RNA contained therein was then extracted, followed by isolation of short-stranded RNA. The resulting purified solution was analyzed using a two-step RT-qPCR reaction in an apparatus that maintains ideal temperature conditions for the separate steps, which are repeated cyclically, in the presence of standard and sequence-specific chemicals, i.e., miRNA-specific stem-loop RT primers, miRNA-specific forward and reverse PCR primers, and miRNA-specific MGB probes. In each step, the fluorescent signal emitted by the probe is measured, and the cycle is repeated, usually 40 to 45 times in total. After the program is finished, the Ct values ​​are read in separate channels, and the results correspond to the original number of nucleic acid molecules monitored. RNA extraction from leukocyte lysate and RT-qPCR analysis are standard in current molecular diagnostics. The procedure is fast, easy to perform, and can be easily automated. Therefore, this diagnostic method is suitable for implementation in many genetic laboratories and for wide use in clinical practice.

[0014] A normal distribution of the expression of the selected miRNAs was determined based on samples from women who had physiological pregnancies without complications. These levels were then compared with the miRNA levels in samples from women who developed any of the complications monitored during pregnancy, and the results were statistically treated using Kruskal-Wallis and Mann-Whitney tests. For each individual pregnancy complication, a specific set of miRNAs was selected. All of these miRNAs are upregulated before the onset of a given complication (except for PTB, where all selected miRNAs are downregulated), and their combination can be used to predict the complication with a significantly low false positive rate and a significantly high sensitivity. A commonly accepted value is a false positive rate of 10%.

[0015] The selection of miRNAs suitable as biomarkers for predicting individual pregnancy complications and for detecting one risk factor for developing pregnancy complications (CHH) is as follows: miR-146a-5p: upregulated in GH, CHH, PE, FGR, and SGA; downregulated in PTB miR-181a-5p: Increased expression in GH, CHH, PE, FGR, and SGA miR-155-5p: upregulated in CHH, PE, FGR, and SGA; downregulated in PTB miR-20a-5p, miR-143-3p, miR-195-5p: Increased expression in CHH, PE, FGR, and SGA miR-145-5p: upregulated in GH, PE, and FGR; downregulated in PTB miR-20b-5p, miR-126-3p: upregulated in CHH, PE, and SGA; downregulated in PTB miR-16-5p: upregulated in PE, FGR, and SGA; downregulated in PTB miR-574-3p: upregulated in PE and FGR; downregulated in PTB miR-342-3p: upregulated in FGR; downregulated in PTB miR-100-5p: Increased expression in FGR and SGA miR-1-3p, miR-499a-5p: Increased expression in CHH and SGA miR-103a-3p: Increased expression in PE and FGR miR-21-5p: upregulated in PE; downregulated in PTB miR-17-5p: Increased expression in PE miR-24-3p, miR-26a-5p, miR-92a-3p, miR-133a-3p, miR-210-3p, miR-221-3p: Downregulated by PTB miR-130b-3p: Increased expression in SGA

[0016] Preeclampsia (PE) It was found that women who developed PE during pregnancy could be best predicted by monitoring the increased expression of the following eight miRNAs in peripheral venous whole blood taken during the first trimester: miR-20a-5p, miR-21-5p, miR-126-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, and miR-574-3p. Using this method, it was possible to predict 53.0% of cases with a false positive rate (FPR) of 10% without further clinical examination of the woman or knowing her medical history. Prior art methods using predefined prediction algorithms within computer applications for clinical and laboratory tests and obstetric and gynecological databases based on medical history could only detect 33.3% of cases in the same group of women. Thus, the development of PE can be successfully predicted using methods utilizing miRNA biomarkers with a significantly higher probability than prior art techniques. Also, using a method utilizing a predefined prediction algorithm, it was only possible to predict early forms of PE, i.e., PE occurring before the 34th week of pregnancy, whereas the method utilizing miRNA biomarkers was able to predict any form of PE (early PE, late PE, mild PE and severe PE) occurring at any stage of pregnancy from the 20th week onwards.

[0017] Fetal growth restriction (FGR) It was found that in women who experienced FGR during pregnancy, the best prediction was achieved by monitoring the increased expression of the following 10 miRNAs in peripheral venous whole blood taken during the first trimester: miR-16-5p, miR-20a-5p, miR-100-5p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-342-3p, miR-574-3p. Using this method, it was possible to predict 40.2% of cases with an FPR of 10% without further clinical examination of the woman or knowing her medical history. Prior art methods using predefined prediction algorithms within computer applications for clinical and laboratory examinations and obstetric and gynecological databases based on medical history were only able to detect 28.0% of cases in the same group of women. Thus, the method using miRNA biomarkers can be used to successfully predict FGR with a significantly higher probability than the prior art methods. Also, the method using a predefined prediction algorithm can only predict FGR occurring before the 37th week of pregnancy, whereas the method using miRNA biomarkers can predict FGR occurring at any stage of pregnancy from 20 weeks onwards, including FGR occurring after the 37th week of pregnancy.

[0018] Preterm birth (PTB) in the form of spontaneous preterm birth (SPTB) or premature rupture of membranes (PPROM) without other pregnancy complications (GH, PE, FGR or SGA) It was found that in women who gave birth prematurely, the best prediction was achieved by monitoring the decreased expression of the following 12 miRNAs in peripheral venous whole blood taken during the first trimester: miR-16-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-133a-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-210-3p, miR-342-3p. Using this method, it was possible to predict 52.8% of cases with a FPR of 10% without further clinical examination of the woman or knowledge of her medical history. It was also possible to predict cases in which premature birth would occur without any obvious clinical factors, which is currently virtually impossible in the first trimester of pregnancy. Prior art methods utilizing predefined prediction algorithms were only able to predict this complication to a very limited extent, and only in cases of SPTB (20% of primiparous women and 30% of women who have given birth twice or more). Furthermore, using predefined prediction algorithm methods, only early forms of SPTB, i.e. SPTB occurring before 34 weeks of gestation, could be predicted, whereas miRNA biomarker methods could predict both SPTB and PPROM occurring at any stage of gestation after 24 weeks of gestation.

[0019] Chronic Hypertension (CHH) In women with chronic hypertension, which is itself a risk factor for the development of PE, the following four miRNAs were frequently upregulated in peripheral venous whole blood taken during the first trimester: miR-1-3p, miR-20a-5p, miR-126-3p, and miR-146a-5p. Using this method, it was possible to detect 79.3% of cases with an FPR of 10% without further clinical examination of the woman or knowing her medical history. Prior art methods utilizing predefined prediction algorithms within computer applications for obstetric and gynecological databases are based in particular on the patient's medical history, and CHH is part of the data as one of the risk factors when assessing the risk of developing PE. If, during the collection of the medical history, the patient does not provide this medical history data, it is not included in the calculation of the risk of developing a subsequent PE.

[0020] Small for gestational age (SGA) It was found that women whose fetuses experienced SGA during pregnancy could be best predicted by monitoring the increased expression of the following eight miRNAs in peripheral venous whole blood taken during the first trimester: miR-1-3p, miR-20a-5p, miR-20b-5p, miR-126-3p, miR-130b-3p, miR-146a-5p, miR-181a-5p, miR-499a-5p. Using this method, it was possible to predict 83.8% of cases with an FPR of 10% without further clinical examination of the woman or knowing her medical history. Prior art methods that utilize predefined prediction algorithms within computer applications for obstetric and gynecological databases are unable to predict this complication.

[0021] Gestational hypertension (GH) It was found that in women who experienced GH during pregnancy, the best prediction was achieved by monitoring the increased expression of the following miRNA in peripheral venous whole blood taken during the first trimester: miR-181a-5p. Using this method, it was possible to predict 22.9% of cases with an FPR of 10%, without further clinical examination of the woman or knowing her medical history. Prior art methods utilizing predefined prediction algorithms within computer applications for obstetric and gynecological databases are unable to predict this complication. [Brief description of the drawings]

[0022] [Figure 1] Figure 1 presents the ROC (Receiver Operating Characteristic) curves of the combined screening and individual miRNAs obtained from the statistical analysis of the increased expression of eight selected miRNAs (miR-20a-5p, miR-21-5p, miR-126-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-574-3p) for PE prediction. [Diagram 2]Figure 2 presents the ROC curves of the combined screening and individual miRNAs obtained from the statistical analysis of the increased expression of 10 selected miRNAs (miR-16-5p, miR-20a-5p, miR-100-5p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-342-3p, miR-574-3p) for FGR prediction. [Diagram 3] Figure 3 shows the ROC curves of the combined screening and individual miRNAs obtained from the statistical analysis of the decreased expression of 12 selected miRNAs (miR-16-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-133a-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-210-3p, miR-342-3p) for predicting PTB in the form of SPTB or PPROM without developing other pregnancy complications (GH, PE, FGR or SGA). [Figure 4] Figure 4 presents the ROC curves of the combined screening and individual miRNAs obtained from the statistical analysis of the elevated expression of four selected miRNAs (miR-1-3p, miR-20a-5p, miR-126-3p, miR-146a-5p) for the detection of CHH. [Diagram 5] Figure 5 presents the ROC curves of the combined screening and individual miRNAs obtained from the statistical analysis of the elevated expression of eight selected miRNAs (miR-1-3p, miR-20a-5p, miR-20b-5p, miR-126-3p, miR-130b-3p, miR-146a-5p, miR-181a-5p, miR-499a-5p) for the prediction of SGA. [Figure 6] FIG. 6 presents the ROC curve obtained from the statistical analysis of the elevated expression of selected miRNAs (miR-181a-5p) for GH prediction. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Example 1 Example 1 describes the general implementation of an RT-qPCR assay to measure miRNA abundance in peripheral venous whole blood test and reference samples, which were normalized against simultaneously measured abundance of selected endogenous controls (RNU58A and RNU38B).

[0024] RNA was isolated from the thawed leukocyte lysate using a mixture of acidic phenol and chloroform. The long RNA was further removed from the obtained RNA and the short RNA was enriched using a column with glass fiber filters and different concentrations of ethanol in separate isolation steps. The isolated RNA containing the short RNA was directly used as a template for a two-step RT-qPCR reaction. Reverse transcription was performed under the following conditions: 16°C for 30 min, 42°C for 30 min and 85°C for 5 min. Then, polymerase chain reaction was performed under the following conditions: 95°C for 10 min, 95°C for 15 s and 60°C for 1 min. After this step, fluorescence was measured each time in the FAM and ROX channels (passive reference for normalization of fluorescence). This cycle was repeated a total of 40 to 45 times. After the end of this program, the Ct values ​​of the individual channels were read. Within one sample, Ct values ​​were obtained in the FAM channel for the measured miRNA or for the short RNA that served as an endogenous control. These values ​​correspond to the individual gene expression in the biological sample. Normalized expression values ​​are obtained by subtracting the Ct values ​​of the endogenous controls (geometric mean of RNU58A and RNU38B) from the Ct values ​​of the miRNAs in the measured samples. For relative quantification, the expression of all investigated miRNAs and the endogenous control is also measured simultaneously in a reference sample used in all analyses performed.

[0025] Example 2 Example 2 describes the general implementation of statistical analysis of selected miRNA level data.

[0026] Due to the non-normal distribution of the data according to the Shapiro-Wilk test, non-parametric tests are used to evaluate the experimental data. The gene expression of miRNAs is compared between the individual groups using the Mann-Whitney test, and if more than two groups are compared, a Kruskal-Wallis test is used followed by a post-hoc analysis. The statistical significance level is set at a p<0.05 value. Receiver Operating Characteristic (ROC) curves are also constructed for each miRNA. The area under the curve, the sensitivity and specificity of the individual miRNAs, as well as the optimal cut-off value (the so-called criterion) are evaluated. Furthermore, the optimal cut-off value and the sensitivity of a given miRNA biomarker are determined with a specificity of 90.0%, which corresponds to information on the proportion of women with increased or decreased expression of a specific miRNA with a false positive rate (FPR) of 10.0%. Furthermore, a statistical analysis combining logistic regression and ROC analysis is performed to select the optimal combination of miRNA biomarkers for a given situation. This application gives the following parameters: area under the curve, sensitivity, specificity, optimal cut-off value and the sensitivity of a given combination of miRNA biomarkers at 90.0% specificity.

[0027] Example 3 Example 3 describes the collection and selection of a suitable set of biological samples to develop a method for predicting pregnancy complications using cardiovascular miRNAs as biomarkers.

[0028] 200 μL of peripheral venous whole blood are collected from approximately 12,000 women between the 10th and 13th week of pregnancy. A leukocyte lysate is prepared by removing red blood cells, then flash frozen and stored at -80°C. After the patient's birth, samples are specifically selected from women whose complete health is known throughout the entire period of pregnancy, including all complications and the birth process. 80 patients with a physiological pregnancy process, i.e., not having developed any complications, and with a negative result in the first trimester prenatal screening using a prior art method that utilizes a predefined prediction algorithm within a computer application for obstetric and gynecological databases, are selected as a control group. For the investigation of individual complications, the following patient groups are selected: 66 patients diagnosed with PE during pregnancy, 82 patients diagnosed with FGR during pregnancy, 106 patients who had premature birth (SPTB or PPROM) and did not experience other complications at the same time (GH, PE, FGR or SGA), 29 patients with chronic hypertension, 37 patients diagnosed with SGA during pregnancy, and 83 patients diagnosed with GH during pregnancy. The blood samples of these selected patients are analyzed according to the procedure described in Example 1 to measure the levels of 25 selected miRNAs (miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-100-5p, miR- 103a-3p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p, miR-574-3p). In Examples 4 to 9, in order to predict individual pregnancy complications with high reliability, more than half of the preferred miRNAs shown in each Example are used every time. The highest reliability is achieved by using all the preferred miRNAs shown in each Example.

[0029] Example 4 Example 4 describes the use of selected miRNA markers in selected patient samples to successfully predict PE.

[0030] 66 monitored patients develop PE during pregnancy, 17 patients have mild PE, and 49 patients have severe PE. Of the monitored patients, 14 deliver before 34 weeks of gestation (early PE), and 52 deliver after 34 weeks of gestation (late PE). The blood samples of these selected patients are analyzed according to the procedure described in Example 1 to measure the levels of eight selected miRNAs (miR-20a-5p, miR-21-5p, miR-126-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-574-3p). Increased expression of these selected miRNA biomarkers, whose levels exceed the minimum value determined by statistical analysis at an FPR of 10%, was observed in 35 of 66 patients (9 mild PE, 26 severe PE, 5 early PE and 30 late PE), which corresponds to a good prediction in 53.0% of cases. Statistical analysis of the obtained data provides the following specificity, sensitivity, 95% CI and cut-off values:

[0031] [Table 1]

[0032] [Table 2]

[0033] [Table 3]

[0034] [Table 4]

[0035] [Table 5]

[0036] [Table 6]

[0037] [Table 7]

[0038] [Table 8]

[0039] [Table 9]

[0040] Example 5 Example 5 describes the successful prediction of FGR using selected miRNA markers in selected patient samples.

[0041] 82 monitored patients were diagnosed with FGR during pregnancy, 5 patients delivered before 32 weeks of gestation (early FGR) and 77 delivered after 32 weeks of gestation (late FGR). Blood samples from these selected patients were analyzed according to the procedure described in Example 1 to measure the levels of 10 selected miRNAs (miR-16-5p, miR-20a-5p, miR-100-5p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-342-3p, miR-574-3p). Increased expression of these selected miRNA biomarkers, whose levels exceed the minimum determined by statistical analysis at an FPR of 10%, was observed in 33 of 82 patients (2 early FGR and 31 late FGR), which corresponds to a good prediction in 40.2% of cases. Statistical analysis of the obtained data provides the following specificity, sensitivity, 95% CI and cut-off values:

[0042]

Table 10

[0043]

Table 11

[0044]

Table 12

[0045]

Table 13

[0046]

Table 14

[0047]

Table 15

[0048]

Table 16

[0049]

Table 17

[0050]

Table 18

[0051]

Table 19

[0052]

Table 20

[0053] Example 6 Example 6 describes the use of selected miRNA markers in selected patient samples to successfully predict PTB in the form of SPTB or PPROM in those without other pregnancy complications (GH, PE, FGR or SGA).

[0054] Of the 106 monitored patients who did not develop other pregnancy complications, spontaneous preterm birth (41 patients) or premature rupture of membranes (65 patients) occurred before 37 weeks of gestation, 29 patients delivered before 34 weeks of gestation, and 77 patients delivered after 34 weeks of gestation. Blood samples from these selected patients were analyzed according to the procedure described in Example 1 to measure the levels of 12 selected miRNAs (miR-16-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-133a-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-210-3p, miR-342-3p). A decrease in expression of these selected miRNA biomarkers, whose levels are below the maximum determined by statistical analysis at an FPR of 10%, was observed in 56 of 106 patients (13 SPTB, 43 PPROM, 12 PTB before 34 weeks, 44 PTB after 34 weeks), which corresponds to a good prediction in 52.8% of cases. Statistical analysis of the obtained data provides the following specificity, sensitivity, 95% CI and criterion values:

[0055] [Table 21]

[0056] [Table 22]

[0057] [Table 23]

[0058] [Table 24]

[0059] [Table 25]

[0060] [Table 26]

[0061] [Table 27]

[0062] [Table 28]

[0063] [Table 29]

[0064] [Table 30]

[0065] [Table 31]

[0066] [Table 32]

[0067] [Table 33]

[0068] Example 7 Example 7 describes the successful detection of CHH using selected miRNA markers in selected patient samples.

[0069] 29 patients monitored are CHH. Blood samples from these selected patients are analyzed according to the procedure described in Example 1 to measure the levels of four selected miRNAs (miR-1-3p, miR-20a-5p, miR-126-3p, miR-146a-5p). Increased expression of these selected miRNA biomarkers, whose levels exceed the minimum value determined by statistical analysis at FPR 10%, is observed in 23 of the 29 patients, which corresponds to successful detection in 79.3% of cases. Statistical analysis of the obtained data provides the following values ​​of specificity, sensitivity, 95% CI and criteria:

[0070] [Table 34]

[0071] [Table 35]

[0072] [Table 36]

[0073] [Table 37]

[0074] [Table 38]

[0075] Example 8 Example 8 describes the use of selected miRNA markers in selected patient samples to successfully predict SGA.

[0076] The fetuses of 37 monitored patients were diagnosed with SGA during pregnancy, and these patients delivered between 33 and 40 weeks of gestation, 4 patients delivered before 34 weeks of gestation (early SGA), and 33 delivered after 34 weeks of gestation (late SGA). Blood samples of these selected patients were analyzed according to the procedure described in Example 1 to measure the levels of 8 selected miRNAs (miR-1-3p, miR-20a-5p, miR-20b-5p, miR-126-3p, miR-130b-3p, miR-146a-5p, miR-181a-5p, miR-499a-5p). Increased expression of these selected miRNA biomarkers, whose levels exceed the minimum value determined by statistical analysis at FPR10%, was observed in 31 of the 37 patients (1 early SGA, 30 late SGA), which corresponds to a good prediction in 83.8% of cases. Statistical analysis of the data obtained provides the following specificity, sensitivity, 95% CI and criterion values:

[0077] [Table 39]

[0078] [Table 40]

[0079] [Table 41]

[0080] [Table 42]

[0081] [Table 43]

[0082] [Table 44]

[0083] [Table 45]

[0084] [Table 46]

[0085] [Table 47]

[0086] Example 9 Example 9 describes the successful prediction of GH using selected miRNA markers in selected patient samples.

[0087] 83 of the monitored patients have been diagnosed with GH during pregnancy. Blood samples from these selected patients are analyzed according to the procedure described in Example 1 to measure the levels of the selected miRNA (miR-181a-5p). Increased expression of this selected miRNA biomarker, whose levels exceed the minimum value determined by statistical analysis at an FPR of 10%, is observed in 19 of the 83 patients, which corresponds to a good prediction in 22.9% of cases. Statistical analysis of the obtained data provides the following specificity, sensitivity, 95% CI and criterion values:

[0088] [Table 48] [Industrial Applicability]

[0089] The method for predicting pregnancy complications based on the expression profile of cardiovascular miRNAs is industrially applicable in gynecological and obstetric clinical practice and in laboratory analysis of collected biological material samples.

Claims

1. Pregnant women are screened to measure the expression profile of one or more miRNAs in peripheral venous whole blood collected between 10 and 13 weeks of gestation, wherein the one or more miRNAs are selected from the group consisting of miR-1-3p, which measures its increased expression, miR-16-5p, which measures its increased or decreased expression, miR-17-5p, which measures its increased expression, miR-20a-5p, which measures its increased expression, miR-20b-5p, which measures its increased or decreased expression, miR-21-5p, which measures its increased or decreased expression, miR-24-3p, which measures its decreased expression, miR-26a-5p, which measures its decreased expression, miR-92a-3p, which measures its decreased expression, miR-100-5p, which measures its increased expression, miR-103a-3p, which measures its increased expression, miR-126-3p, which measures its increased expression, miR-130-5p, which measures its increased expression, miR-132-5p, which measures its increased expression, miR-134-5p, which measures its increased expression, miR-136-5p, which measures its increased expression, miR-138-5p, which measures its increased expression, miR-139-5p, which measures its increased expression, miR-140-5p, which measures its increased expression, miR-142-5p, which measures its increased expression, miR-130b-3p, miR-133a-3p for measuring its decreased expression, miR-143-3p for measuring its increased expression, miR-145-5p for measuring its increased or decreased expression, miR-146a-5p for measuring its increased or decreased expression, miR-155-5p for measuring its increased or decreased expression, miR-181a-5p for measuring its increased expression, miR-195-5p for measuring its increased expression, and miR-196-5p for measuring its decreased expression. The present invention relates to a method for predicting pregnancy complications in the form of pre-eclampsia, fetal growth restriction, gestational hypertension, small for gestational age, and premature birth, and a method for detecting chronic hypertension, characterized in that the miR-210-3p, which measures the expression of miR-210-3p, which measures the expression reduction of miR-221-3p, which measures the expression reduction of miR-221-3p, which measures the expression reduction of miR-342-3p, which measures the expression reduction or increase ...499a-5p, and which measures the expression reduction of miR-574-3p.

2. The method according to claim 1, characterized in that the screened miRNAs for predicting pre-eclampsia are upregulated miR-20a-5p, upregulated miR-21-5p, upregulated miR-126-3p, upregulated miR-143-3p, upregulated miR-145-5p, upregulated miR-146a-5p, upregulated miR-181a-5p and upregulated miR-574-3p.

3. The method of claim 1, characterized in that the screened miRNAs for predicting fetal growth restriction are upregulated miR-16-5p, upregulated miR-20a-5p, upregulated miR-100-5p, upregulated miR-143-3p, upregulated miR-145-5p, upregulated miR-146a-5p, upregulated miR-181a-5p, upregulated miR-195-5p, upregulated miR-342-3p and upregulated miR-574-3p.

4. The method according to claim 1, characterized in that the screened miRNA for predicting pregnancy-induced hypertension is upregulated miR-181a-5p.

5. The method according to claim 1, characterized in that the screened miRNAs for predicting small for gestational age babies are upregulated miR-1-3p, upregulated miR-20a-5p, upregulated miR-20b-5p, upregulated miR-126-3p, upregulated miR-130b-3p, upregulated miR-146a-5p, upregulated miR-181a-5p and upregulated miR-499a-5p.

6. 2. The method of claim 1, wherein the screened miRNAs for predicting preterm birth are: under-expressed miR-16-5p, under-expressed miR-20b-5p, under-expressed miR-21-5p, under-expressed miR-24-3p, under-expressed miR-26a-5p, under-expressed miR-92a-3p, under-expressed miR-133a-3p, under-expressed miR-145-5p, under-expressed miR-146a-5p, under-expressed miR-155-5p, under-expressed miR-210-3p and under-expressed miR-342-3p.

7. 7. The method of claim 6, wherein the preterm birth is in the form of spontaneous preterm birth or premature rupture of membranes.

8. The method according to claim 1, characterized in that the screened miRNAs for detecting chronic hypertension are upregulated miR-1-3p, upregulated miR-20a-5p, upregulated miR-126-3p and upregulated miR-146a-5p.

Citation Information

Patent Citations

  • Methods and compositions for diagnosing complications of pregnancy

    JP2011510623A

  • preeclampsia

    WO2016151287A1

  • Postpartum epigenetic profile of cardiovascular micrornas in women exposed to pregnancy-related complications

    WO2020088704A1

  • Postpartal epigenetic profile of cardiovascular microRNAs in children born of complicated pregnancies - new biomarkers of cardiovascular risk

    CZ308102B6

  • Postpartal epigenetic profile of cardiovascular microRNAs in children born from complicated pregnancies - new cardiovascular risk biomarkers

    CZ308178B6